
The Celiac Disease Treatment Market was valued at $450.00 million in 2025 and is projected to reach $1.99 billion by 2035, growing at a CAGR of 16.0 percent over 2026 to 2035, according to Strategic Revenue Insights. Clinical pipeline progress is the main driver, because there is still no approved drug and many patients stay symptomatic despite a strict gluten-free diet.
Click here for free sample PDF: https://www.strategicrevenueinsights.com/industry/celiac-disease-treatment-market
Celiac Disease Treatment Market Key Takeaways
- The market expands 4.4x over the decade, from $450.00 million to $1.99 billion.
- Gluten-free diet support is the largest segment with 58% of 2025 revenue.
- Enzyme therapeutics lead the drug classes with 34%, while vaccines grow fastest at 24.7%.
- North America holds 45% of 2025 revenue, and Asia Pacific grows fastest at 19.2%.
- Online pharmacies are the fastest distribution channel at 20.4%.
What Is Driving Growth
Four drivers add about 13.9 percentage points to growth and two restraints take back 4.1. Clinical pipeline progress adds 4.5 points as enzyme, tolerance and TG2 inhibitor candidates move toward late-stage trials. Unmet need beyond diet adds 3.8, rising diagnosis rates through tTG-IgA screening and wider clinician awareness add 3.2, and FDA fast-track designations and EMA scientific advice add 2.4 by speeding development paths. The largest driver and the largest restraint are two sides of the same fact: no drug is approved yet.
Segments, Regions and Key Players
Retail pharmacies lead the distribution channel with 41.5% of 2025 revenue, while online pharmacies grow fastest. Gastroenterology clinics are the largest end user at 43% and also the fastest growing at 17.2%, reflecting how care for refractory patients is concentrated with specialists. Growth over the forecast comes less from today’s products than from the first targeted therapies reaching patients.
North America leads on diagnosis rates and trial activity, while Asia Pacific is the fastest region as awareness and screening widen. The five largest companies hold about 40% of revenue. Takeda, Dr. Falk Pharma, Amgen, Teva, Merck KGaA and AstraZeneca are among the key players.
Frequently Asked Questions
How large is the celiac disease treatment market?
It is worth $450.00 million in 2025 and is projected to reach $1.99 billion by 2035, a 16.0% CAGR from 2026 to 2035.
Which drug class grows fastest?
Vaccines grow fastest at 24.7% a year, while enzyme therapeutics are the largest drug class with 34% of 2025 revenue.
Which region leads the market?
North America leads with 45% of 2025 revenue, and Asia Pacific is the fastest-growing region at 19.2%.
About Strategic Revenue Insights Inc.
Strategic Revenue Insights Inc., a subsidiary of SRI Consulting Group Ltd headquartered in London, provides syndicated market research reports, consulting and strategic insights. Contact: sales@strategicrevenueinsights.com | www.strategicrevenueinsights.com
